About us

Nerviano Medical Sciences S.r.l is focused on discovery and clinical development of small molecule NCEs for oncology. The company takes innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients.

Our current pipeline consists of NCEs, which all originate from our well validated oncology drug discovery platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

Nerviano Medical Sciences S.r.l combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharma (manufacturing).

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib. Moreover, we are also developing a proprietary payload platform for generation of novel Antibody-Drug Conjugates (ADCs).

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunies of promising assets for clinical development.